This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Vyepti® Alternatives

Vyepti®

(eptinezumab-jjmr)
Vyepti
    Migraine
  • Emgality®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were stuffy nose and scratchy throat. Vyepti is FDA approved for the following indications: Migraine prevention.

Ajovy®

(Fremanezumab)
Ajovy
    Migraine
  • Emgality®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions. Ajovy is FDA approved for the following indications: Migraine prevention.

Dosage & Administration

Administration
Intravenous infusion (must be diluted)
Subcutaneous
Dosing
100 mg every 3 months or 300 mg (for some patients)
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each)
Latin Shorthand
100 mg q3mo
225 mg/mo or 675 mg q3mo

Financial Assistance

Copay
$0
$5
Annual Cap
$200 per infusion for administration costs
Patient specific maximum benefit.
Assistance Expiration
Calendar year
12/31/2023
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Vyepti® vs. Emgality®
  • Vyepti® vs. Aimovig®
  • Vyepti® vs. Nurtec odt®
  • Vyepti® vs. Ubrelvy®
  • Vyepti® vs. Qulipta®

Relevant Resources

Vyepti
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Ajovy
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.